Cardiol Therapeutics Inc Class A (CRDL) - Total Assets
Based on the latest financial reports, Cardiol Therapeutics Inc Class A (CRDL) holds total assets worth CA$23.62 Million CAD (≈ $17.09 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Cardiol Therapeutics Inc Class A net assets for net asset value and shareholders' equity analysis.
Cardiol Therapeutics Inc Class A - Total Assets Trend (2017–2025)
This chart illustrates how Cardiol Therapeutics Inc Class A's total assets have evolved over time, based on quarterly financial data.
Cardiol Therapeutics Inc Class A - Asset Composition Analysis
Current Asset Composition (December 2025)
Cardiol Therapeutics Inc Class A's total assets of CA$23.62 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 90.7% |
| Accounts Receivable | CA$226.19K | 1.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Cardiol Therapeutics Inc Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CRDL company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cardiol Therapeutics Inc Class A's current assets represent 99.5% of total assets in 2025, an increase from 77.2% in 2017.
- Cash Position: Cash and equivalents constituted 90.7% of total assets in 2025, up from 73.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 22.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 1.0% of total assets.
Cardiol Therapeutics Inc Class A Competitors by Total Assets
Key competitors of Cardiol Therapeutics Inc Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Cardiol Therapeutics Inc Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.16 | 4.52 | 7.31 |
| Quick Ratio | 4.16 | 4.52 | 7.30 |
| Cash Ratio | 0.00 | 4.36 | 0.00 |
| Working Capital | CA$17.85 Million | CA$24.66 Million | CA$17.45 Million |
Cardiol Therapeutics Inc Class A - Advanced Valuation Insights
This section examines the relationship between Cardiol Therapeutics Inc Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.37 |
| Latest Market Cap to Assets Ratio | 6.29 |
| Asset Growth Rate (YoY) | -25.9% |
| Total Assets | CA$23.62 Million |
| Market Capitalization | $148.65 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cardiol Therapeutics Inc Class A's assets at a significant premium (6.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cardiol Therapeutics Inc Class A's assets decreased by 25.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cardiol Therapeutics Inc Class A (2017–2025)
The table below shows the annual total assets of Cardiol Therapeutics Inc Class A from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$23.62 Million ≈ $17.09 Million |
-25.87% |
| 2024-12-31 | CA$31.86 Million ≈ $23.05 Million |
-13.18% |
| 2023-12-31 | CA$36.70 Million ≈ $26.55 Million |
-40.83% |
| 2022-12-31 | CA$62.03 Million ≈ $44.87 Million |
-29.41% |
| 2021-12-31 | CA$87.88 Million ≈ $63.57 Million |
+452.92% |
| 2020-12-31 | CA$15.89 Million ≈ $11.50 Million |
+2.52% |
| 2019-12-31 | CA$15.50 Million ≈ $11.21 Million |
-37.20% |
| 2018-12-31 | CA$24.68 Million ≈ $17.86 Million |
+666.45% |
| 2017-12-31 | CA$3.22 Million ≈ $2.33 Million |
-- |
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for … Read more